




 Statins are known for their blood cholesterol lowering effect ans are widely used in patients 
with cardiovascular and metabolic diseases. Research over the past three decades shows that 
statins have diverse effects on different pathophysiological pathways involved in 
angiogenesis, inflammation, apoptosis, and anti-oxidation, leading to new therapeutic 
options. Recently, statins have attracted considerable attention for their immunomodulatory 
effect. Since immune reactivity has been implicated in a number of retinal diseases such as 
uveitis,age related macular degeneration (AMD) and diabetic retinopathy, there is now a 
growing body of evidence supporting the beneficial effects of statins in these retinopathies. 
This review evaluates the relation between statins and the pathophysiological basis of these 
disease, focusing on their potential role in treatment.  
 
  Methods: a PubMed database search and literature review was conducted.   
  Results: Among AMD patient there is inconsistent evidence regarding protection against 
development of early AMD or delaying disease progression, though they have been found to 
reduce the risk of developing choroidal neovascular membranes (CNV). In patients with 
retinal vein occlusion there was no evidence to support a therapeutic benefit or a protective 
role of statins. Inpatients with diabetic retinopathy statins demonstrate a reduction in disease 
progression and improved resolution of diabetic macular oedema (DMO).  Among patients 







In August 2017 we performed a comprehensive literature review using the PubMed online 
database. We used the following terms ‘statins immunomodulatory effect’; ‘statins and 
retinal disease’; ‘statins and the eye’; ‘statins and age related macular degeneration’; ‘statins 
and AMD’; ‘statins and diabetic retinopathy’; ‘statins and retinal vein occlusion’; and ‘statins 
and uveitis’. We only included papers written in English. There were no date limits. We 
reviewed all articles and included those of interest focusing on animal models, laboratory 
research and clinical studies . We manually searched the reference lists of these manuscripts 




Background of statins 
 
Statins, also known as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors, have long been used for controlling blood cholesterol levels and reducing the risk 
of cardiovascular morbidity and mortality. While their mechanism of action in vascular 
disease is established, evidence is accumulating regarding alternative immunomodulatory 
roles that may enhance their cardiovascular effect as well as play a role in treating 
inflammatory diseases (1).  
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Statins were discovered in the early 1970s  from Penicillium citrinium cultures (2). Further 
research showed that these molecules strongly inhibit the rate-limiting enzyme in cholesterol 
biosynthesis, HMG-CoA reductase, which is responsible for the conversion of HMG-CoA to 
L-mevalonate and finally to farnesylpyrophosphate (FPP, the precursor for cholesterol 
synthesis) (3). Another product of the L-mevalonate pathway is geranylgeranylpyrophspohate 
(GGPP), which is synthesized from FPP. FPP and GGPP are both essential isoprenoids and 
serve as lipid attachments for various intracellular proteins that are thought to have an 
immunomodulatory effect by acting as adjuncts for different cell signaling processes, such as 
GTPases RAS, RAC and RHO  (4). 
 
Early evidence of the immunosuppressive effect of statins comes from studies on c-reactive 
protein (CRP), a systemic inflammatory biomarker, in patients following myocardial infarcts.  
Individuals with elevated serum CRP levels >3 mg/L have an increased risk of cardiovascular 
events and use of statins results in a reduction of CRP levels independent of their effect on 
blood cholesterol levels (5, 6). Endothelial function studies (7) as well as clinical trials from 
organ transplantation (8) and stroke prevention (9), support their additional 
immunomodulatory effect unrelated to lowering cholesterol. This has led to a 
recommendation to give cardiac transplant patients statins irrespective of their blood 
cholesterol levels (10) (1). 
There is evidence supporting an inflammatory role in the pathophysiology of many retinal 
diseases and statins have been  investigated in conditions such as cataract (11), glaucoma 
(12), diabetic retinopathy (13) and age-related macular degeneration (AMD) (14), with mixed 
results regarding their effect. There are also preliminary results suggesting it may reduce the 
extent of scarring following rhegmatogenous retinal detachment (15).  
 4 
 
Statin’s immunomodulatory effect    
  
The immunomodulatory effect of statins is exerted either directly on cells, such as interfering 
with T lymphocyte proliferation (16, 17), inhibiting the expression of co-stimulatory 
molecules CD80 and CD86 on B cells (REF) or through inhibition of cellular interactions and 
signaling molecules such as tumor necrosis factor α (TNF-α)  (18), a potent pro-inflammatory 
cytokine that induces apoptosis of retinal cells (19). By influencing the cytokine balance from 
pro-inflammatory to anti-inflammatory, statins modulate the immune response and acheive 
an immunosuppressive effect (20) (21). Additionally, statins alter the interaction between the 
vascular endothelium and lymphocytes by blocking the intercellular adhesion molecule 1 
(ICAM1) pathway, which facilities transvascular migration of lymphocytes(22), thereby 
reducing the number of lymphocytes reaching the sites of inflammation. For a full description 
of statin immunomodulatory pathways please refer to figure 1. 
 
Age-Related Macular Degeneration  
 
While the pathophysiology of AMD is not completely understood, there are well established 
risk factors, such as increasing age, smoking, genetic predisposition and increased body mass 
index (23).Pathological changes including lipid accumulation under Bruch’s membrane, 
lipoprotein metabolism and inflammation, are thought to play a role in disease development 
and progression to the its more advanced stages(24, 25). Drusen, the hallmark of early AMD 
are lipid-rich deposits located between the retinal pigment epithelium (RPE) and Bruch’s 
membrane (26). The interaction between these lipids and reactive oxygen species results in 
the formation of peroxidised lipids that trigger local inflammation and destruction(REF), 
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which can  either lead to the development of choroidal neovascularization (CNV) by 
releasing angiogenic cytokines or geographic atrophy by a direct toxic effect on the RPE cells 
(27). Several risk factors are shared for both cardiovascular disease and AMD, and serum 
levels for cardiovascular disease biomarkers (CRP and homocysteine) are significantly higher 
in AMD patients, suggesting similar pathophysiological processes such as chronic 
inflammation and atherosclerosis (29).  




Statins in AMD 
 
The potential role for statins in the management of AMD is supported through several 
pathophysiological mechanisms. Statins can preserve the vascular supply to the outer retina, 
by reducing artherosclerotic changes, thus maintaing the clearance of lipoproteins produced 
by the RPE and delaying the development of drusen. (30), (31) Their anti-nflammatory 
properties may further affect the inflammatory process underlying the development and 
progression of AMD,(32) and their effect on induction of heme oxygenase 1 and 
downregulation of LDL and peroxidised lipids,(34) may protect the outer retina, choroid, and 
RPE from oxidative damage (30). Lastly, statins’ inhibit the activation of macrophages and 
the subsequent release of pro-inflammatory cytokines and matrix metalloproteinases (MMP 
2), which are found in the CNV complex, delaying CNV development (30).   
A meta-analysis of 15 studies examining the role of statins in AMD found a robust protective 
effect in early disease (35). They reduced the risk of early AMD by 17 %, whereas in late 
AMD their use was associated with a reduced risk of CNV development, but with no effect 
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on the development of geographic atrophy (GA). . The Blue Mountain Eye Study that 
followed 3654 people at10 years intervals showed that statin users had a reduced risk of 
developing soft drusen, but did not affect the incidence of progressing to early AMD (38). 
This was replicated in the Beaver Dam Eye Study and the Rotterdam Eye Study, where no 
association was found between statin use and developing AMD at 5 years follow-up (39, 40).  
However, statins users in the Beaver Dam Eye Study were 32% less likely to develop soft 
indistinct drusen, 36% less likely to have large drusen (≥125 μm) compared to non-statin 
users 71% less likely to present with late disease (39).  In-line with these results, Maguire and 
colleagues examined 744 patients for the development of advanced AMD (GA or 
neovascularaiztion) and found no protective effect for statins after 5 years follow-up (41).  
Several studies examined the effect of statins on development of disease specific features and 
progression to advanced disease. A cross-sectional study with a mean duration of statin 
intake of 61.1 months found that statins were associated with a lower risk of AMD in 
subjects’ ≥ 68 years old, which was more pronounced the longer statins were used (42).  An 
open-label study examined the effect of high dose (80 mg) atorvastatin in patients with high 
risk features for progression to advanced AMD (presence of many large soft drusenoiod 
deposits) and showed a trend towards reduced number of drusenoid RPE detachments and a 
visual gain of 3 letters on average after 1 year follow-up (14).  Two randomised controlled 
trials aimed to accurately determine the effect of statins on AMD patients.  The first 
examined the effect of 20 mg of simvastatin on 30 subjects for three months but did not show 
a statistically significant effect on vision (43). In the second study, 114 subjects were 
randomised to either 40 mg simvastatin or placebo. The results showed a four-fold decrement 
in the risk of disease progression in the treated group, and was even more prominent among 
patients with the complement factor H (CFH) allele (44), where the odds ratio for disease 
progression was 0.08. In 2015 a Cochrane systematic review and meta-analysis concluded 
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that there is inadequate evidence to support the role of statins in prevention or alteration of 
AMD progression (45). Tables 1 & 2 summarise the trials that offer support or do not for the 
protective role of statins in AMD . 
 
Diabetic Retinopathy  
 
Diabetic retinopathy (DR) is a frequent complication of diabetes and increases in prevalence 
with disease duration. The most common causes of vision loss in diabetes are macular 
oedema and complications related to proliferative diabetic retinopathy. There is mounting 
evidence regarding endothelial dysfunction in diabetes and inflammatory processes leading to 
the development of DR (46). High glucose levels lead to activation of protein kinase C and 
induction of the aldose reductase pathway with overproduction of free radicals, endothelial 
cell injury and upregulation of pro-inflammatory cytokines such as TNF-α, IL-1, ICAM1 and 
IL-6 (47, 48). This can lead to breakdown of the blood retinal barrier (BRB) resulting in loss 
of vascular integrity, which results in increased permeability, leading to macular oedema as 
well as compromised blood supply and retinal ischaemia. (49). More advance, proliferative 
diabetic retinopathy (PDR) is partly mediated by transforming growth factor β2 (TGF β2) 
which is up-regulated in diabetes. TGF β is responsible for the transformation of RPE and 
hyalocytes into myofibroblastic cells and induces contraction of fibrocellular complexs, 
which is realted to developing vitreous haemorrhages and traction retinal detachment (50), 
resulting in vision loss.  Hypercholesterolemia, in addition to hyperglycaemia, is regarded as 
a strong risk factor for endothelial dysfunction (51) leading to diabetic macular oedema (52). 
Total cholesterol and LDL were found to be significantly higher in subjects with clinically 
significant macular oedema (53)(54, 55) and were a significant risk factor for retinal hard 




Statins have a role in maintaining the stability of the BRB by reducing reactive oxygen 
species, increasing nitrous oxide (NO) levels and increasing the numbers of endothelial 
progenitor cells (EPC), which are thought to play a role in maintaining a functional BRB. 
This results in improve blood flow velocity, reduce the vascular resistance and retinal 
perfusion of subjects with diabetic retinopathy (57, 58). Moreover, Atorvastatin was found to 
have pleiotropic functions on RPE cells including anti-proliferation, anti-contraction, and 
anti-adhesion (59). In PDR, statins are known to suppress TGF β and have been shown to 
suppress the formation of retinal neovascular tufts and delay the progression of PDR in 
animal models (60).  
 
 
Statin clinical trials in diabetic retinopathy   
 
The association between serum cholesterol and DR was first reported by Dornan et al (62). 
Extensive evidence linking elevated serum lipids and the increased risk of hard exudates 
comes from the early treatment diabetic retinopathy study (54) and the Wisconsin 
epidemiology study of diabetic retinopathy (63). High serum cholesterol levels were found to 
be a significant contributor to the extent of developing retinal hard exudates and patients with 
higher serum cholesterol levels at baseline had a 50% risk of vision loss compared to those 
with lower lipid levels (64) (55). The diabetic control and complication trial (65) showed that 
serum lipids, mainly the triglycerides to HDL ratio and LDL levels were risk factors for 
DMO and hard exudate formation. The study highlighted the potential role of lipid-lowering 
agents in reducing the risk of DMO. Furthermore, treatment with statins resulted in a 
reduction of the amount of lipids within the retina, seen on histopathological examination of 
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retinas from patients with high serum cholesterol and DMO (66). However, other studies 
looking at the total cholesterol level as a risk factor for developing DR were  less conclusive 
(67). While the Chennai urban rural epidemiology study (68) found total cholesterol to be an 
independent risk factor for the development of DR, cholesterol was found to have a 
protective effect in the Singapore Malay eye study (69). In yet another study, blood 
triglyceride and LDL cholesterol levels were significantly associated with DR and diabetic 
macular oedema (DMO) respectively (70).  
 
Statins and other lipid lowering drugs have been extensively studied as treatments for 
diabetic retinopathy. A study on the use of pravastatin demonstrated a reduction in hard 
exudates in all patients and reduced numbers of microaneurysms in 67% of patients. (71)  
Simvastatin 20mg was reported to delay the progression of DR and prevent the development 
of vision compared with placebo treated controls. (72) Similarly, treatment with atorvastatin 
resulted ina 66% reduction in hard exudates and leakage on fluorescein angiography among 
eyes with DMO and dislipidemia (74). However, it was not found to be beneficial in DR in 
30 diabetic subjects with normal serum lipid levels (75). The combination of atorvastatin and 
fibrates demonstrated a significant reduction in macular oedema in 47 diabetic patients with 
non-proliferative DR (76), as well as reducing the rate of recurrent vitreous haemorrhage in 
eyes with PDR. (77)  
 
Two randomised controlled trials, the fenofibrate intervention and event lowering in diabetes 
(FIELD) and action to control cardiovascular risk in diabetes (ACCORD) examined the 
effect of fenofibrate, a non-statin drug that  reduces triglycerides and LDL cholesterol, alone 
or together with simvastatin respectively. In both studies, over 5 years follow-up a 
significantly positive effect was found in reducing DR progression  and the addition of 
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simvastatin augmented the control of the DR (78-80). This led to less need for other 
treatment measures, such as focal laser in the FIELD study . These effects were cholesterol 
independent and may be attributed to anti-inflammatory, anti-apoptotic and vasodilatory 
effects which are NO mediated (81, 82). Finally, the improved effect observed by combining 
statins and fenofibrate may be due to a synergistic action that is independent of their 
cholesterol lowering effect. Despite the positive effect observed on DMO, statins were less 
effective in preventing the occurrence of mild DR and no recommendations could be made 
regarding  initiating lipid lowering drugs in patients with normal serum lipid levels. Tables 3 
& 4 summarise the trials that offer support or do not for the protective role of statins in DR. . 
Retinal vein occlusion  
 
Retinal vein occlusion (RVO) is the second most common cause of retinal vascular disease 
after DR (83). Vision loss is secondory to macular oedema and or retinal ischaemia, which 
can lead to neovascularisation and high risk of tractional retinal detachment and neovascular 
glaucoma.  Atherosclerosis, among other cardovascular risk factors such as hyperlipdeima, 
diabetes and hypertension, contributes to the pathophysiology of RVO (84). Hyperlipideamia 
was more than twofold more common in patients with all types of RVO compared to controls 
(85). Raised serum lipids may change plasma viscosity and alter platelet function, which 
predsiposes to thrombosis and blood stasis (86). A number of inflammatory cytokines and 
growth factors may also be upregulated in response to the onset of retinal ischaemia (87), 
which may predispose to a state of chronic inflammation (88). Statins, in addition to their 
anti-inflammatory action, were shown to have a potential protective effect on the 
microvascular endothelium in retinal ischaemia models (89). While low doses promoted 
vascular repair mechanism through upregulating VEGF and NO levels, higher doses resulted 
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in cell death due to depletion of intracellular cholesterol and disruption of key structures 
within the cell.  
 
There is little clinical evidence regarding the role of statins in the management of RVO, or in 
preventing its development.  A retrospective study of RVO patients, as well as patients with a 
high risk of developing RVO ( defined as those having hypertension and primary open angle 
glaucoma), no clear preventative or therapeutic benefit could be found after 43 months 




Uveitis mainly affects young people and carries a significant risk of vision loss (91). It can be 
associated with an underlying systemic disease, though most cases remain idiopathic. 
Corticosteroids represent the mainstay of the treatment, however, steroids are not ideal for 
long-term therapy because they are associated with a wide array of side effects particularly 
increasing total serum cholesterol levels and induction of diabetes and hypertension, thus 
increasing their cardiovascular risks. Similarly, other immunosuppressive drugsmay also 
have significant side effects includingincreasing cardiovascular morbidity (92). 
 
Statins have been shown to have a number of anti-inflammatory and immunomodulatory 
effects, specifically their ability to reduce key inflammatory cytokines such as IL-6, IL8 and 
TNF α, as well as prevent leukocyte adhesion to vascular endothelium (5, 22). The role of 
statins has been extensively studied in a mouse model of experimental autoimmune 
uveoretinitis, where it was found that they reduce the clinical and histological scores of 
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inflammation and inhibit T lymphocyte recruitment into the retina (93). In a mouse model of 
acute autoimmune retinal disease, statins were found to inhibit leukocyte infiltration into the 
retina and reduce retinal vascular leakage (94). Treatment with statins also resulted in 
improved vascular stability in a rodent model of lipopolysaccharides-induced liver 
microvascular dysfunction (95).  
Clinical studies in multiple sclerosis (MS) patients showed a positive effect of simvastatin on 
brain atrophy suggesting these drugs cross the blood-brain barrier  and can play a role in 
controlling inflammatory diseases. (96) In rheumatoid arthritis  statins have a potential 
benefit in controlling disease activity manifesting as improvement in disease activity scores 
and reducing the number of tender and swollen joints. (97) Ocular involvement is common in 
many of these conditions and statins may offer an additional treatment approach to such 
patients. In a retrospective population-based study, use of statins was found to have a 
protective effect on uveitis development over a period of two years (98). The study identified 
108 incident cases of uveitis with an incidence of 19% among statin users compared to 30% 
in patients not  treated with statins. Another study also reported a twofold reduction in the 
risk of ocular inflammatory disease in male patients who used statins compared to a control 
group over a five years period  (99). Although these findings did not reach statistical 
significance, the risk reduction was greater with longer duration of statin use. These studies 
suggest that statins have potential benefits in patients with ocular inflammatory disease.  
 
To address the question of whether there could be therapeutic benefits of statins with respect 
to disease control and dose of anti-inflammatory medications in patients with a diagnosis of 
uveitis, there is an ongoing phase II RCT comparing the effect of simvastatin 80 mg once 
daily versus placebo among patients with sight-threatening uveitis. This may support the role 
of simvastatin in treating such patients, beyond reducing the cardiovascular risks related to 
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long-term exposure to systemic immunosuppressive drugs and corticosteroids, especially 
given the relatively low side effect profile of statins when compared to other 




The potential role of statins in ocular disease is supported by the understanding of their 
mechanism of action, not only in reducing blood cholesterol levels, but also therough direct 
vascular and anti-inflammatory mechanisms. However, the summation of clinical studies 
offers conflicting results and the use of these drugs remain inconclusive. This may be related 
to the different treatment regimens and follow-up lengths used in the various studies, with 
good support for reducing the risk of CNV in AMD patients, as well as reducing the 
progression of DR and promoting the resolution of DMO in patients with dislipidemia. In 
RVO, the effect of statins was not obvious and there is limited data in other ocular diseases. 
As such, at this time there remains no clear recommendation to add statins, purely for their 
anti-inflammatory and immunomodulatory effects to the treatment of patients with ocular 
diseases. However, when other risk factors, such as hyperlipidaemia, diabetes and 
hypertension exist, statins remain an invaluable option to decrease cholesterol and reduce 
cardiovascular risks factors.  There are encouraging results that support the role of statins in 
ocular diseases and further studies may provide clearer evidence in support of this treatment 
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